- Conditions
- Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Necitumumab, Nab-Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Orlando, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 1,450
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 44
- States / cities
- Palo Alto, California • Stanford, California • Denver, Colorado + 35 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, paclitaxel, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Buffalo, New York • Cleveland, Ohio
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Paclitaxel, Carboplatin, CT-322, Bevacizumab, Bevacizumab placebo (ie saline solution)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • San Diego, California • Orlando, Florida + 17 more
- Conditions
- Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
- Interventions
- BXQ-350, Placebo
- Drug · Other
- Lead sponsor
- Bexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 26
- States / cities
- Hot Springs, Arkansas • Springdale, Arkansas • Long Beach, California + 22 more
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, microarray analysis, biopsy, neoadjuvant therapy
- Drug · Genetic · Procedure
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
- Interventions
- azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Interventions
- Nab paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 1 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel
- Drug
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 9
- States / cities
- Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, radiation therapy, surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 13 more
- Conditions
- First Line Non-Small Cell Lung Cancer
- Interventions
- Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 21
- States / cities
- Huntsville, Alabama • Surprise, Arizona • San Diego, California + 18 more
- Conditions
- Head and Neck Cancer
- Interventions
- Cisplatin, Paclitaxel, Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation, Triple endoscopy and biopsy
- Drug · Radiation · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
- Interventions
- dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis
- Drug · Biological · Procedure + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Malignant Solid Neoplasm, ALK Positive, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- Ceritinib, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Gastro-Oesophageal Cancer
- Interventions
- Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil
- Drug · Biological
- Lead sponsor
- Australasian Gastro-Intestinal Trials Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more
- Conditions
- Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- Interventions
- Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Fort Wayne, Indiana • Lexington, Kentucky + 3 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2)
- Drug
- Lead sponsor
- Jina Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Columbus, Georgia • Springfield, Missouri • Canton, Ohio
- Conditions
- Advanced Gastric Cancer, Gastro-esophageal Junction Cancer
- Interventions
- AUY922, Docetaxel, Irinotecan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Lafayette, Indiana • Baltimore, Maryland + 3 more
- Conditions
- Bladder Cancer
- Interventions
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Docetaxel, Paclitaxel, Vinflunine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 931 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Las Vegas, Nevada + 3 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Needle core biopsies, Needle core biopsies of metastatic lesion
- Procedure
- Lead sponsor
- Jewish General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, in vitro-treated peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Endometrial Cancer
- Interventions
- Pembrolizumab, Vaginal cuff brachytherapy (VCB), Paclitaxel, Carboplatin
- Drug · Radiation
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana • Oklahoma City, Oklahoma
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Breast Biopsy Procedure, Carboplatin, Cyclophosphamide, Darolutamide, Doxorubicin, Epirubicin, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Surgical Procedure, Ultrasound Imaging
- Procedure · Drug · Biological
- Lead sponsor
- Vandana Abramson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee